{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:44:52Z","timestamp":1790948692467,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100006244","name":"Stichting Kinderen Kankervrij","doi-asserted-by":"publisher","award":["320"],"award-info":[{"award-number":["320"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Aprepitant is used for the treatment of chemotherapy induced nausea and vomiting. A liquid formulation is needed for treatment of young children. However, the commercial (powder for) suspension was not available worldwide for a prolonged period of time and, therefore, a 10\u2005mg\/mL aprepitant oral suspension was extemporarily prepared to prevent suboptimal antiemetic treatment. The current pharmacokinetic study was developed to investigate whether this extemporaneous oral suspension offers an appropriate treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 49 pediatric patients (0.7\u201317.9 years) 235 plasma concentrations were collected. Patients were either treated with our extemporaneous oral suspension (n\u2009=\u200926; 53%), commercially available capsules (n\u2009=\u200918; 37%), or the intravenous prodrug formulation of aprepitant (fosaprepitant, n\u2009=\u20095; 10%). Pharmacokinetic analyses were performed using nonlinear mixed effects modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A one-compartment model adequately described the pharmacokinetics of aprepitant in children. The bioavailability of the extemporaneous oral suspension was not significantly different to that of the capsules (P\u2009=\u20090.26). The observed bioavailability throughout the total population was 83% (95% CI 69%-97%). The absorption of the extemporaneous oral suspension was 39.4% (95%CI 19.5\u201357.4%) faster than that of capsules (mean absorption time of 1.78\u2005h (95%CI 1.32\u20132.35), but was comparable to that of the commercial oral suspension. The median area under the curve after (fos)aprepitant was 22.2\u2005mg\/L*h (range 8.9\u201350.3\u2005mg\/L*h) on day 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our extemporaneous oral suspension is an adequate alternative for the commercially (un)available oral suspension in young children. An adequate exposure to aprepitant in children was yielded and the bioavailability of the extemporaneous suspension was comparable to capsules.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221089243","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:05:21Z","timestamp":1649073921000},"page":"899-904","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["A simple extemporaneous oral suspension of aprepitant yields sufficient pharmacokinetic exposure in children"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3448-7665","authenticated-orcid":false,"given":"A Laura","family":"Nijstad","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Department of Pharmacology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"de Vos-Kerkhof","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine F","family":"Enters-Weijnen","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne D","family":"van de Wetering","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J E","family":"Tissing","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pediatric Oncology and Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidwien M","family":"Hanff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Lange","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs M","family":"Tibben","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michel","family":"Zwaan","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pediatric Oncology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D R","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Department of Pharmacology, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"bibr1-10781552221089243","unstructured":"Sharp M, Dohme BV. Summary of product characteristics: emend, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emend-epar-product-information_en.pdf (2008, accessed 5 November 2021)."},{"key":"bibr2-10781552221089243","unstructured":"Sharp M, Dohme BV. Summary of product characteristics: ivemend, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ivemend-epar-product-information_en.pdf (2013)."},{"key":"bibr3-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70061-6"},{"key":"bibr4-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3384-y"},{"key":"bibr5-10781552221089243","doi-asserted-by":"publisher","DOI":"10.2147\/nano.2007.2.1.13"},{"key":"bibr6-10781552221089243","unstructured":"European Medicines Agency. Emend: EPAR - scientific discussion, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/emend-epar-scientific-discussion_en.pdf (2006)."},{"key":"bibr7-10781552221089243","unstructured":"European Medicines Agency. Emend-H-C-527-X-0049\/G: EPAR - assessment report - extension, https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/emend-h-c-527-x-0049\/g-epar-assessment-report-extension_en.pdf (2016)."},{"key":"bibr8-10781552221089243","first-page":"528","volume":"25","author":"Chain A","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"key":"bibr9-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-008-0539-5"},{"key":"bibr10-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219828806"},{"key":"bibr11-10781552221089243","volume":"122639","author":"Nijstad AL","year":"2021","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"bibr12-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5309.122"},{"key":"bibr13-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-007-9066-0"},{"key":"bibr14-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"bibr15-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9542-0"},{"key":"bibr16-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"bibr17-10781552221089243","first-page":"2","author":"Boeckmann AJ","year":"2011","journal-title":"NONMEM Part V"},{"key":"bibr18-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"bibr19-10781552221089243","unstructured":"RC Team. R: a language and environment for statistical computing.\n                      R Found Stat Comput Vienna\n                      ."},{"key":"bibr20-10781552221089243","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0713-y"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221089243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221089243","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221089243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:51Z","timestamp":1777688811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221089243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1177\/10781552221089243"],"URL":"https:\/\/doi.org\/10.1177\/10781552221089243","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]}}}